Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Integrin alpha 4 beta 1

Integrin alpha 4 beta 1

Brief Information

Name:Integrin alpha-4/beta-1
Target Synonym:Integrin alpha4beta1
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

IT1-H52W1-ELISA
 Integrin alpha 4 beta 1 ELISA

Immobilized Natalizumab at 1 μg/mL (100 μL/well) can bind Human ITGA4&ITGB1 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT1-H52W1) with a linear range of 1-16 ng/mL (QC tested).

IT1-H82W1-ELISA
 Integrin alpha 4 beta 1 ELISA

Immobilized Natalizumab at 1 μg/mL (100 μL/well) can bind Biotinylated Human ITGA4&ITGB1 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT1-H82W1) with a linear range of 2-31 ng/mL (QC tested).

Synonym Name

Integrin alpha 4 beta 1,ITGA4&ITGB1,ITGA4&B1

Background

Integrins are transmembrane proteins that mediate interactions between adhesion molecules on adjacent cells and/or the extracellular matrix (ECM). Integrins have diverse roles in several biological processes including cell migration during development and wound healing, cell differentiation, and apoptosis. Their activities can also regulate the metastatic and invasive potential of tumor cells. Integrin alpha 4 beta 1(Alpha-4/beta-1) is receptors for fibronectin. Integrin alpha-4/beta-1 is a receptor for VCAM1 and recognizes the sequence Q-I-D-S in VCAM1.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Carotegrast methyl AJM-300 Approved Ea Pharma, Eisai Co Ltd Carogra Japan Colitis, Ulcerative Ea Pharma Co Ltd 2022-03-28 Colitis, Ulcerative Details
Natalizumab biosimilar(Polpharma Biologics) PB-006; DST-356A1 Approved Polpharma Biologics Sa Tyruko United States Crohn Disease; Multiple Sclerosis Sandoz Inc 2023-08-24 Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Crohn Disease Details
Natalizumab BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E Approved Biogen Inc, Perrigo Llc Tysabri, Antegran, Antegren United States Multiple Sclerosis; Crohn Disease Biogen Idec 2004-11-23 Multiple Sclerosis, Relapsing-Remitting; Epilepsies, Partial; Arthritis, Rheumatoid; Graft vs Host Disease; Stroke; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis; Multiple Myeloma; Demyelinating Diseases; Myositis, Inclusion Body; Crohn Disease Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
RBx-7796 RBx-7796 Clinical Sun Pharmaceutical Industries Ltd Rhinitis, Allergic; Asthma Details
Alintegimod 7HP349; 7-HP-349; 7HP-349 Phase 1 Clinical 7 Hills Pharma LLC Solid tumours Details
LLP2A alendronate Phase 1 Clinical University Of California Osteonecrosis; Osteoporosis; Bone Diseases, Metabolic; Bone Diseases Details
ATL-1102 ATL-1102; TV-1102; ATL/TV-1102; ISIS-107248 Phase 2 Clinical Ionis Pharmaceuticals Inc Multiple Sclerosis; Muscular Dystrophy, Duchenne Details
AS-101 PRX-0001/AS101; WAX-120337; IVAX-Q-101; IVX-Q-101; CB-06-02; AS-101; PRX-001; PRX-0002/AS101 Phase 2 Clinical Biomas Ltd Alopecia; HIV Infections; Warts; Myelodysplastic Syndromes; Psoriasis; Leukemia, Myeloid, Acute; Thrombocytopenia; Macular Degeneration; Dermatitis, Atopic; Condylomata Acuminata Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message